Meda has acquired exclusive European rights to a new formulation of imiquimod from Graceway Pharmaceuticals. The new formulation is 3,75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). This product has recently been approved in the US and Canada.
Today, Meda markets a higher strength (5%) of imiquimod in Europe under the trademark Aldara. In 2009, sales of Aldara were approximately 500 MSEK....
Toll-like receptors that activate immune cells being developed as alternative cure to cancer
The Medical News
16. September 2009 05:27
The development of cancer involves the uncontrolled growth of normal cells of the body. Our immune system can sense the growth of the tumor cells and can usually eliminate them using direct killing mechanisms, mediated by natural killer cells and cytotoxic T lymphocytes. However, the tumor has an arsenal of strategies to counteract...
ScienceDaily (Apr. 28, 2009) — In a case study of a type of melanoma skin cancer typically found on chronically sun-exposed skin, Saint Louis University researchers found that imiquimod, a topical cream, produced good results for patients when used together with surgery to treat the cancer, potentially helping doctors cut less.
The study, published in Dermatologic Surgery, looked at two cases of the most common type of melanoma of the head and neck, lentigo maligna (LM), a type of "melanoma-in-...
NEW YORK (Reuters Health) - Applying a prescription cream (imiquimod) for 24 weeks is effective for the treatment of a type of skin lesion called actinic keratosis, caused by long-term exposure to the sun, according to researchers from Mount Sinai Medical Center in New York.
Dr. Mark Lebwohl and colleagues enrolled 20 patients with actinic keratosis into a 28-week trial. Fifteen patients completed the trial and five...
Actinic keratoses: Patients benefit from a variety of advances in clinical approaches to treatment
Jan 17, 2009
Dermatology Times E-News
Kohala Coast, HI — Because there are multiple effective modalities that can be used for the treatment of actinic keratoses (AKs), clinicians should consider both the overall goal(s) they want to achieve and recent developments in therapeutic approaches, said Roger I. Ceilley, M.D., while speaking at the Winter Clinical Dermatology...
